PL444504A1 - Sulfoksymina butioniny do zastosowania w leczeniu chłoniaka Burkitta - Google Patents

Sulfoksymina butioniny do zastosowania w leczeniu chłoniaka Burkitta

Info

Publication number
PL444504A1
PL444504A1 PL444504A PL44450423A PL444504A1 PL 444504 A1 PL444504 A1 PL 444504A1 PL 444504 A PL444504 A PL 444504A PL 44450423 A PL44450423 A PL 44450423A PL 444504 A1 PL444504 A1 PL 444504A1
Authority
PL
Poland
Prior art keywords
burkitt
lymphoma
treatment
buthionine sulfoximine
buthionine
Prior art date
Application number
PL444504A
Other languages
English (en)
Other versions
PL247705B1 (pl
Inventor
Marta Kazimierska
Aleksandra Leśniewska
Anja Bakker
Arjan Diepstra
Marta Kasprzyk
Marta Podralska
Karolina Rassek
Joot Kluiver
Anke Van Den Berg
Natalia Rozwadowska
Agnieszka Dzikiewicz-Krawczyk
Original Assignee
Instytut Genetyki Człowieka Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Genetyki Człowieka Polskiej Akademii Nauk filed Critical Instytut Genetyki Człowieka Polskiej Akademii Nauk
Priority to PL444504A priority Critical patent/PL247705B1/pl
Publication of PL444504A1 publication Critical patent/PL444504A1/pl
Publication of PL247705B1 publication Critical patent/PL247705B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Zgłoszenie wynalazku dotyczy sulfoksyminy butioniny do zastosowania w leczeniu chłoniaka Burkitta oraz sposobu obniżenia żywotności komórek nowotworowych ex vivo z udziałem sulfoksyminy butioniny.
PL444504A 2023-04-20 2023-04-20 Sulfoksymina butioniny do zastosowania w leczeniu chłoniaka Burkitta PL247705B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL444504A PL247705B1 (pl) 2023-04-20 2023-04-20 Sulfoksymina butioniny do zastosowania w leczeniu chłoniaka Burkitta

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL444504A PL247705B1 (pl) 2023-04-20 2023-04-20 Sulfoksymina butioniny do zastosowania w leczeniu chłoniaka Burkitta

Publications (2)

Publication Number Publication Date
PL444504A1 true PL444504A1 (pl) 2024-10-21
PL247705B1 PL247705B1 (pl) 2025-08-25

Family

ID=93155141

Family Applications (1)

Application Number Title Priority Date Filing Date
PL444504A PL247705B1 (pl) 2023-04-20 2023-04-20 Sulfoksymina butioniny do zastosowania w leczeniu chłoniaka Burkitta

Country Status (1)

Country Link
PL (1) PL247705B1 (pl)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018172559A2 (en) * 2017-03-23 2018-09-27 Istituto Superiore di Sanità Compositions and methods for the treatment of disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018172559A2 (en) * 2017-03-23 2018-09-27 Istituto Superiore di Sanità Compositions and methods for the treatment of disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E. H. MUSTAFA ET AL.: "Asian Pac J Cancer Prev. 2015; 16 (8), 3213-3222", 2-DEOXY-D-GLUCOSE SYNERGIZES WITH DOXORUBICIN OR L-BUTHIONINE SULFOXIMINE TO REDUCE ADHESION AND MIGRATION OF BREAST CANCER CELLS. *
K. ONO ET AL.: "Br J Cancer 1986; 54, 749-754", COMBINED EFFECT OF BUTHIONINE SULFOXIMINE AND CYCLOPHOSPHAMIDE UPON MURINE TUMOURS AND BONE MARROW. *
K.S. LEE ET AL.: "Korean J Intern Med. 1992; 7(2); 111-117", EFFECTS OF BUTHIONINE SULFOXIMINE TREATMENT ON CELLULAR GLUTATHIONE LEVELS AND CYTOTOXICITIES OF CISPLATIN, CARBOPLATIN AND RADIATION IN HUMAN STOMACH AND OVARIAN CANCER CELL LINES. *
M. CRESCIMANNO ET AL.: "J. Chemother. 1994; 6(5): 343-348", EFFECT OF BUTHIONINE SULFOXIMINE ON THE SENSITIVITY TO DOXORUBICIN OF PARENT AND MDR TUMOR CELL LINES *

Also Published As

Publication number Publication date
PL247705B1 (pl) 2025-08-25

Similar Documents

Publication Publication Date Title
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
CY1107121T1 (el) Ρυθμιση διαφοροποιησης αιματοποιητικων βλαστικων κυτταρων με τη χρηση ανθρωπινων μεσυγχυματικων βλαστικων κυτταρων
ATE377435T1 (de) Vaginalduschen und applikatoren für vaginalduschen
DE60118723D1 (de) Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten
ATE369871T1 (de) Verfahren zur behandlung von hautkrebs mittels zusammensetzungen, die einen endothelinrezeptor-b-hemmer enthalten
DK1082410T3 (da) Humane CD45 - og/eller fibroblast mesenchymale stamceller
EA200600424A1 (ru) Применение полипептидов семейства купредоксинов при лечении рака
ATE417923T1 (de) Knorpelersatzimplantat und verfahren zur herstellung eines knorpelersatzimplantats
ATE312635T1 (de) Ventilanordnung
ATE531383T1 (de) Therapeutische verwendung eines wachstumsfaktors, metrnl
ATE527378T1 (de) Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE385807T1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
DK1274464T3 (da) Sammensætninger og fremgangsmåder til regulering af proteinekspression i tarm
MX2024015041A (es) Fitusiran para el tratamiento de la hemofilia a y b
EP4271393A4 (en) BIOLOGICALLY STABLE XNAZYME THAT EFFICIENTLY BLOOMS GENE EXPRESSION IN CELLS
PL444504A1 (pl) Sulfoksymina butioniny do zastosowania w leczeniu chłoniaka Burkitta
CY1124082T1 (el) Μεθοδοι θεραπειας με χρηση κινητοποιητων βλαστικων κυτταρων και ανοσοκατασταλτικων παραγοντων
DE60022478D1 (de) Verwendung des vaskularen endothelialen wachstumsfaktors zur behandlung von erektilen dysfunktionen
ITMI20022118A1 (it) Procedimento per la coltura su larga scala di t-linfociti in un sistema omogeneo.
DE60043888D1 (de) Oberfläche für zellkultur
DE602005021681D1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
DK1778834T5 (da) Fremgangsmåder til anvendelse af regenerative celler i behandlingen af renale sygdomme og lidelser
PL438908A1 (pl) Sposób hodowli immortalizowanych linii ludzkich mezenchymalnych komórek macierzystych (MSC), kompozycja czynników aktywnych zawartych w nadsączu otrzymanych tym sposobem i zastosowanie